Arcutis Enjoys Seborrheic Dermatitis Win But Experts Itching For Psoriasis Approval
Executive Summary
The firm is planning a US NDA filing after its roflumilast formulation succeeded in a pivotal seborrheic dermatitis study but analysts are keener on a ‘make or break’ approval in psoriasis.
You may also be interested in...
Arcutis’s Phase III AD Win Bodes Well For Soon-To-Report Second Study
One analyst said efficacy data for roflumilast in INTEGUMENT-1 suggest limited competitiveness against Incyte’s topical JAK inhibitor, Opzelura, while others were more optimistic.
Arcutis Launches Zoryve For Psoriasis As A New Topical In A Growing Category
Zoryve joins Dermavant's Vtama as a new topical drug with a broad label for plaque psoriasis and offers some points of differentiation, including price.
Keeping Track: US FDA Clears Vtama, But Not Bimekizumab Or Ycanth; Tibsovo Takes RTOR To Frontline AML Setting
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.